A molecular diagnostics company is raising fresh capital for a test to predict the likelihood of a precancerous condition becoming esophageal cancer. The idea is that by detecting the condition earlier and more accurately, it could lead to better outcomes.
Cernostics’ approach is called TissueCipher Pathology. It combines digital imaging pathology, fluorescence biomarkers, informatics and EMR systems. The goal is to speed up, reduce the cost and improve the quality of testing and develop individualized patient treatments.
Danville, Pennsylvania-based Cernostics raised $1.4 million from three investors, according to a Form D filing with the U.S. Securities and Exchange Commission. It has previously received investments from Ben Franklin Technology Partners of Northeastern Pennsylvania. Cernostics formed a partnership with Geisinger Health System in 2010.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Barrett’s esophagus is a condition that can develop as a result of severe gastroesophageal reflux disease or heartburn. Cells in the lower esophagus become damaged, frequently from repeated exposure to stomach acid.
Esophageal cancer has one of the highest mortality rates among cancers, and 17,990 new cases are diagnosed in the United States each year, according to data from the American Cancer Society.
The company wants to replace a current test that generates false positives and can’t detect abnormal cell structures.
Earlier this year, Cernostics added two scientific advisers — Dr. John M. Inadomi, the division chief for Gastroenterology at the University of Washington, and Robert F. Murphy, a professor of computational biology and director of the Computational Biology center at Carnegie Mellon University.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
